Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Ovarian Cancer, TNBC, SCLC, Other Solid Tumours”

5 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 5 of 5 results

Early research (Phase 1)Study completedNCT02482311
What this trial is testing

Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours

Who this might be right for
Ovarian Cancer, TNBC, SCLC, Other Solid Tumours
AstraZeneca 92
Early research (Phase 1)Looking for participantsNCT06465069
What this trial is testing

LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

Who this might be right for
Metastatic Solid TumorRecurrent Solid TumorAdvanced Solid Tumor+11 more
Eli Lilly and Company 420
Testing effectiveness (Phase 2)Looking for participantsNCT04585750
What this trial is testing

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Who this might be right for
Advanced Solid TumorAdvanced Malignant NeoplasmMetastatic Cancer+27 more
PMV Pharmaceuticals, Inc 300
Early research (Phase 1)Study completedNCT03329950
What this trial is testing

CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies

Who this might be right for
MelanomaNon-small Cell Lung CancerBreast Cancer+23 more
Celldex Therapeutics 132
Early research (Phase 1)Looking for participantsNCT05005403
What this trial is testing

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

Who this might be right for
Non-Small Cell Lung CancerHead and Neck Squamous Cell CarcinomaMicro Satellite Stable Colorectal Cancer+4 more
AbbVie
694